person · Reporting owner
van den Broek Richard
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | Director | June 11, 2026 | June 15, 2026 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | June 11, 2026 | June 16, 2026 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.60 · Expires 2036-06-11 | Direct | 15,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 8,423 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 8,423 · Balance 8,423 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Grant · Acquired 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-19 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 8,423 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020719 · rdgdoc.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,423 Underlying: Common Stock · 8,423 shares Expires 2036-06-11 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 01:06 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020719 · rdgdoc.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:04 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001610717-26-000219 · form4.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 01:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001437749-25-027401 · rdgdoc.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-15 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025. Read SEC document |
| April 08, 2025 Filed Apr 9, 2025 21:26 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001610717-25-000098 · form4.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-04-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 8, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 24, 2024 23:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 11,649 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001437749-24-021129 · rdgdoc.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,649 Underlying: Common Stock · 11,649 shares Expires 2034-06-06 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2024. Read SEC document |
| June 06, 2024 Filed Jun 24, 2024 23:38 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001437749-24-021129 · rdgdoc.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 6, 2024. Read SEC document |
| May 25, 2023 Filed Jun 6, 2023 23:25 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 28,487 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-016801 · rdgdoc.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,487 Underlying: Common Stock · 28,487 shares Expires 2033-05-25 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2023. Read SEC document |
| May 25, 2023 Filed Jun 6, 2023 23:25 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001437749-23-016801 · rdgdoc.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 25, 2023. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-23-000033 · wf-form4_168452752005886.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. F2 · derivative.expiration_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001169245-23-000033 · wf-form4_168452752005886.xml · nonDerivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:44 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-22-000060 · wf-form4_165307944363751.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. F3 · derivative.expiration_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:44 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001169245-22-000060 · wf-form4_165307944363751.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed May 24, 2022 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 79,206 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-22-064005 · tm2216672-4_4seq1.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,206 Underlying: Common Stock · 79,206 shares Expires 2032-05-19 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on August 19, 2022. Read SEC document |
| May 19, 2022 Filed May 24, 2022 00:54 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-22-064005 · tm2216672-4_4seq1.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 19, 2022. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 18:17 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001169245-21-000065 · wf-form4_162284502821041.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2022 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:08 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 9,069 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035012 · doc4.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,069 Underlying: Common Stock · 9,069 shares Expires 2031-05-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:08 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035012 · doc4.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 15:39 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $10.78 | $0.00 |
DisclosureSEC source: 0001209191-20-045891 · doc4.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2030-08-06 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option will vest on August 6, 2021, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 18:58 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001169245-20-000065 · wf-form4_159139791077217.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the 2021 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| May 09, 2019 Filed May 13, 2019 16:38 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $13.23 | $0.00 |
DisclosureSEC source: 0001209191-19-029357 · doc4.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 2,750 shares Expires 2029-05-09 F1 · derivative.exercise_date: The shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the date of the 2020 annual meeting, subject to the reporting person's continuous service through each such date Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 17:03 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-19-015085 · doc4.xml · derivative · entry 2 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months from February 27, 2019, subject to the reporting person's continued service through each such date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 17:03 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-19-015085 · doc4.xml · derivative · entry 1 van den Broek Richard · CIK 0001431872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months from February 27, 2019, subject to the reporting person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.